

## DAFTAR PUSTAKA

- Abouzaid, S., Tian, H., Zhou, H., Kahler, K.H., Harris, M., Kim, E., 2014. Economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia. *Community Ment Health J* 50, 51–58.  
<https://doi.org/10.1007/s10597-012-9561-7>
- Acharya, S., Kim, K.-M., 2021. Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease. *Int J Mol Sci* 22, 4299.  
<https://doi.org/10.3390/ijms22094299>
- Adamu, M.J., Qiang, L., Nyatega, C.O., Younis, A., Kawuwa, H.B., Jabire, A.H., Saminu, S., 2023. Unraveling the pathophysiology of schizophrenia: insights from structural magnetic resonance imaging studies. *Front Psychiatry* 14.  
<https://doi.org/10.3389/fpsy.2023.1188603>
- Ade, K.K., Wan, Y., Hamann, H.C., O'Hare, J.K., Guo, W., Quian, A., Kumar, S., Bhagat, S., Rodriguiz, R.M., Wetsel, W.C., Conn, P.J., Dzirasa, K., Huber, K.M., Calakos, N., 2016. Increased Metabotropic Glutamate Receptor 5 Signaling Underlies Obsessive-Compulsive Disorder-like Behavioral and Striatal Circuit Abnormalities in Mice. *Biol Psychiatry* 80, 522–533.  
<https://doi.org/10.1016/j.biopsych.2016.04.023>
- Albert, P.R., Vahid-Ansari, F., 2019. The 5-HT1A receptor: Signaling to behavior. *Biochimie* 161, 34–45. <https://doi.org/10.1016/j.biochi.2018.10.015>
- Albin, R.L., Bohnen, N.I., Muller, M.L.T.M., Dauer, W.T., Sarter, M., Frey, K.A., Koeppe, R.A., 2018. Regional vesicular acetylcholine transporter distribution in human brain: A [18 F]fluoroethoxybenzovesamicol positron emission tomography study. *Journal of Comparative Neurology* 526, 2884–2897.  
<https://doi.org/10.1002/cne.24541>
- Ali, T., Sisay, M., Tariku, M., Mekuria, A.N., Desalew, A., 2021. Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. *PLoS One* 16. <https://doi.org/10.1371/journal.pone.0257129>
- Alvarez-Herrera, S., Rosel Vales, M., Pérez-Sánchez, G., Becerril-Villanueva, E., Flores-Medina, Y., Maldonado-García, J.L., Saracco-Alvarez, R., Escamilla, R., Pavón, L., 2024. Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia. *Pharmaceuticals* 17, 167. <https://doi.org/10.3390/ph17020167>
- Alwindi, M., Bizanti, A., 2023. Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditions. *Heliyon* 9, e22413.  
<https://doi.org/10.1016/j.heliyon.2023.e22413>
- Amato, D., Canneva, F., Cumming, P., Maschauer, S., Groos, D., Dahlmanns, J.K., Grömer, T.W., Chiofalo, L., Dahlmanns, M., Zheng, F., Kornhuber, J., Prante, O.,

- Alzheimer, C., von Hörsten, S., Müller, C.P., 2020. A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. *Mol Psychiatry* 25, 2101–2118. <https://doi.org/10.1038/s41380-018-0114-5>
- Amato, D., Kruyer, A., Samaha, A.-N., Heinz, A., 2019. Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia. *Front Psychiatry* 10. <https://doi.org/10.3389/fpsy.2019.00314>
- Amato, D., Vernon, A.C., Papaleo, F., 2018. Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability. *Neurosci Biobehav Rev*. <https://doi.org/10.1016/j.neubiorev.2017.09.027>
- Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cini, E., Rossi, M., McCormick, P.J., Corsini, G.U., Maggio, R., Scarselli, M., 2018. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. *Pharmacol Ther*. <https://doi.org/10.1016/j.pharmthera.2018.06.012>
- Aubry, R., Hastings, T., Morgan, M., Hastings, J., Bolton, M., Grummell, M., Killeen, S., Coyne, C., Shorr, R., Solmi, M., 2024. Guideline concordant screening and monitoring of extrapyramidal symptoms in patients prescribed antipsychotic medication: a protocol for a systematic literature review and narrative synthesis. *BMJ Open* 14, e087632. <https://doi.org/10.1136/bmjopen-2024-087632>
- Ayano, G., 2016. Second Generation Antipsychotics: Pharmacodynamics, Therapeutic Effects Indications and Associated Metabolic Side Effects: Review of Articles. *J Schizophr Res*.
- Azam, F., Abugrain, I.M., Sanalla, M.H., Elnaas, R.F., Rajab, I., 2013. In-silico investigation of the structural requirements for the AMPA receptor antagonism by quinoxaline derivatives. *Bioinformation* 9, 864–869. <https://doi.org/10.6026/97320630009864>
- Bak, M., Fransen, A., Janssen, J., Van Os, J., Drukker, M., 2014. Almost all antipsychotics result in weight gain: A meta-analysis. *PLoS One* 9. <https://doi.org/10.1371/journal.pone.0094112>
- Baker, M., Kang, S., Hong, S.-I., Song, M., Yang, M.A., Peyton, L., Essa, H., Lee, S.W., Choi, D.-S., 2023. External globus pallidus input to the dorsal striatum regulates habitual seeking behavior in male mice. *Nat Commun* 14, 4085. <https://doi.org/10.1038/s41467-023-39545-8>
- Baldessarini, R.J., I. Tarazi, F., 2018. Goodman, Gilmans - The Pharmacological Basis of Therapeutics, 13th ed. McGraw Hill Education.
- Baudry, A., Pietri, M., Launay, J.-M., Kellermann, O., Schneider, B., 2019. Multifaceted Regulations of the Serotonin Transporter: Impact on Antidepressant Response. *Front Neurosci* 13. <https://doi.org/10.3389/fnins.2019.00091>

- Benkert, P., Biasini, M., Schwede, T., 2011. Toward the estimation of the absolute quality of individual protein structure models. *Bioinformatics* 27, 343–350. <https://doi.org/10.1093/bioinformatics/btq662>
- Bento, A.P., Gaulton, A., Hersey, A., Bellis, L.J., Chambers, J., Davies, M., Krüger, F.A., Light, Y., Mak, L., McGlinchey, S., Nowotka, M., Papadatos, G., Santos, R., Overington, J.P., 2014. The ChEMBL bioactivity database: an update. *Nucleic Acids Res* 42, D1083–D1090. <https://doi.org/10.1093/nar/gkt1031>
- Berman, H.M., 2000. The Protein Data Bank. *Nucleic Acids Res* 28, 235–242. <https://doi.org/10.1093/nar/28.1.235>
- Beurel, E., Grieco, S.F., Jope, R.S., 2015. Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases. *Pharmacol Ther* 148, 114–131. <https://doi.org/10.1016/j.pharmthera.2014.11.016>
- Bocchio, M., Lukacs, I.P., Stacey, R., Plaha, P., Apostolopoulos, V., Livermore, L., Sen, A., Ansorge, O., Gillies, M.J., Somogyi, P., Capogna, M., 2019. Group II Metabotropic Glutamate Receptors Mediate Presynaptic Inhibition of Excitatory Transmission in Pyramidal Neurons of the Human Cerebral Cortex. *Front Cell Neurosci* 12. <https://doi.org/10.3389/fncel.2018.00508>
- Bolneo, E., Chau, P.Y.S., Noakes, P.G., Bellingham, M.C., 2022. Investigating the Role of GABA in Neural Development and Disease Using Mice Lacking GAD67 or VGAT Genes. *Int J Mol Sci* 23, 7965. <https://doi.org/10.3390/ijms23147965>
- Bordia, T., Zhang, D., Perez, X.A., Quik, M., 2016. Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia. *Exp Neurol* 286, 32–39. <https://doi.org/10.1016/j.expneurol.2016.09.009>
- Bridi, J.C., Hirth, F., 2018. Mechanisms of  $\alpha$ -Synuclein Induced Synaptopathy in Parkinson's Disease. *Front Neurosci* 12. <https://doi.org/10.3389/fnins.2018.00080>
- Brown, D.A., 2018. Regulation of neural ion channels by muscarinic receptors. *Neuropharmacology* 136, 383–400. <https://doi.org/10.1016/j.neuropharm.2017.11.024>
- Brutcher, R.E., Nader, M.A., 2015. Effects of quetiapine treatment on cocaine self-administration and behavioral indices of sleep in adult rhesus monkeys. *Psychopharmacology (Berl)* 232, 411–420. <https://doi.org/10.1007/s00213-014-3672-5>
- Bu, M., Farrer, M.J., Khoshbouei, H., 2021. Dynamic control of the dopamine transporter in neurotransmission and homeostasis. *NPJ Parkinsons Dis* 7, 22. <https://doi.org/10.1038/s41531-021-00161-2>
- Celada, P., Bortolozzi, A., Artigas, F., 2013. Serotonin 5-HT<sub>1A</sub> Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research. *CNS Drugs* 27, 703–716. <https://doi.org/10.1007/s40263-013-0071-0>

- Ceskova, E., 2022. Has the utilization of serotonin receptor antagonism made an impact on schizophrenia treatment? *Expert Opin Pharmacother.*  
<https://doi.org/10.1080/14656566.2022.2137403>
- Chapman, C.A., Nuwer, J.L., Jacob, T.C., 2022. The Yin and Yang of GABAergic and Glutamatergic Synaptic Plasticity: Opposites in Balance by Crosstalking Mechanisms. *Front Synaptic Neurosci* 14.  
<https://doi.org/10.3389/fnsyn.2022.911020>
- Chemel, B.R., Bonner, L.A., Watts, V.J., Nichols, D.E., 2012. Ligand-Specific Roles for Transmembrane 5 Serine Residues in the Binding and Efficacy of Dopamine D1 Receptor Catechol Agonists. *Mol Pharmacol* 81, 729–738.  
<https://doi.org/10.1124/mol.111.077339>
- Chiu, C.Q., Barberis, A., Higley, M.J., 2019. Preserving the balance: diverse forms of long-term GABAergic synaptic plasticity. *Nat Rev Neurosci* 20, 272–281.  
<https://doi.org/10.1038/s41583-019-0141-5>
- Chokhawala, K., Stevens, L., 2024. *Antipsychotic Medications [WWW Document]. StatPearls Publishing.*
- Coleman, J.A., Gouaux, E., 2018. Structural basis for recognition of diverse antidepressants by the human serotonin transporter. *Nat Struct Mol Biol* 25, 170–175. <https://doi.org/10.1038/s41594-018-0026-8>
- Coleman, J.A., Green, E.M., Gouaux, E., 2016. X-ray structures and mechanism of the human serotonin transporter. *Nature* 532, 334–339.  
<https://doi.org/10.1038/nature17629>
- Cookson, J., Pimm, J., 2023. Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine. *BJPsych Adv* 29, 145–150. <https://doi.org/10.1192/bja.2021.49>
- Correll, C.U., Schooler, N.R., 2020. Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. *Neuropsychiatr Dis Treat.*  
<https://doi.org/10.2147/NDT.S225643>
- Courey, T.J., 2007. Detection, Prevention, and Management of Extrapyramidal Symptoms. *The Journal for Nurse Practitioners* 464–469.
- D'Abreu, A., Akbar, U., Friedman, J.H., 2018. Tardive dyskinesia: Epidemiology. *J Neurol Sci.* <https://doi.org/10.1016/j.jns.2018.02.007>
- Daina, A., Michielin, O., Zoete, V., 2019. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. *Nucleic Acids Res* 47, W357–W364. <https://doi.org/10.1093/nar/gkz382>
- de Anda-Jáuregui, G., Guo, K., Hur, J., 2019. Network-based assessment of adverse drug reaction risk in polypharmacy using high-throughput screening data. *Int J Mol Sci* 20. <https://doi.org/10.3390/ijms20020386>

- de Bartolomeis, A., Tomasetti, C., Iasevoli, F., 2015. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. *CNS Drugs* 29, 773–799.  
<https://doi.org/10.1007/s40263-015-0278-3>
- Demirci, Ö., Adar, İ., Erbaş, O., 2023. An Overview of Antipsychotics: Mechanisms of Action. *Journal of Experimental and Basic Medical Sciences* 4, 62–70.  
<https://doi.org/10.5606/jebms.2023.1047>
- Deng, C., Weston-Green, K., Huang, X.F., 2010. The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain? *Prog Neuropsychopharmacol Biol Psychiatry*.  
<https://doi.org/10.1016/j.pnpbp.2009.11.009>
- Devasani, K., Yao, Y., 2022. Expression and functions of adenylyl cyclases in the CNS. *Fluids Barriers CNS* 19, 23. <https://doi.org/10.1186/s12987-022-00322-2>
- dos Santos, R.N., Ferreira, L.G., Andricopulo, A.D., 2018. Practices in Molecular Docking and Structure-Based Virtual Screening. pp. 31–50.  
[https://doi.org/10.1007/978-1-4939-7756-7\\_3](https://doi.org/10.1007/978-1-4939-7756-7_3)
- Ecevitoglu, A., Edelstein, G.A., Presby, R.E., Rotolo, R.A., Yang, J.H., Quiles, T., Okifo, K., Conrad, R.T., Kovach, A., Correa, M., Salamone, J.D., 2023. Effects of the atypical antipsychotic and D3/D2 dopamine partial agonist cariprazine on effort-based choice behavior: implications for modeling avolition. *Psychopharmacology (Berl)* 240, 1747–1757. <https://doi.org/10.1007/s00213-023-06405-8>
- Egerton, A., Bhachu, A., Merritt, K., McQueen, G., Szulc, A., McGuire, P., 2017. Effects of antipsychotic administration on brain glutamate in schizophrenia: A systematic review of longitudinal 1H-MRS studies. *Front Psychiatry*.  
<https://doi.org/10.3389/fpsy.2017.00066>
- Ekhteiari Salmas, R., Serhat Is, Y., Durdagi, S., Stein, M., Yurtsever, M., 2018. A QM protein–ligand investigation of antipsychotic drugs with the dopamine D2 Receptor (D2R). *J Biomol Struct Dyn* 36, 2668–2677.  
<https://doi.org/10.1080/07391102.2017.1365772>
- Elizarraras, J.M., Liao, Y., Shi, Z., Zhu, Q., Pico, A.R., Zhang, B., 2024. WebGestalt 2024: faster gene set analysis and new support for metabolomics and multi-omics. *Nucleic Acids Res* 52, W415–W421. <https://doi.org/10.1093/nar/gkae456>
- Errington, D., Schneider, C., Bouysset, C., Dreyer, F.A., 2025. Assessing interaction recovery of predicted protein-ligand poses. *J Cheminform* 17, 76.  
<https://doi.org/10.1186/s13321-025-01011-6>
- Etminan, M., Procyshyn, R.M., Samii, A., Carleton, B.C., 2016. Risk of extrapyramidal adverse events with aripiprazole. *J Clin Psychopharmacol* 36, 472–474.  
<https://doi.org/10.1097/JCP.0000000000000543>
- Farah, A., 2005. Atypicality of Atypical Antipsychotics, Atypicality of Atypical Antipsychotics Prim Care Companion *J Clin Psychiatry*.

- FDA, 2022. FDA Approved Drug Products: ABILIFY (aripiprazole) tablets for oral use, orally disintegrating tablets, oral solution, injection for intramuscular use only.
- Fernández de Sevilla, D., Núñez, A., Buño, W., 2021. Muscarinic Receptors, from Synaptic Plasticity to its Role in Network Activity. *Neuroscience* 456, 60–70. <https://doi.org/10.1016/j.neuroscience.2020.04.005>
- Foster, D.J., Bryant, Z.K., Conn, P.J., 2021. Targeting muscarinic receptors to treat schizophrenia. *Behavioural brain research* 405, 113201. <https://doi.org/10.1016/j.bbr.2021.113201>
- Frey, K.A., 2017. Molecular Imaging of Extrapyrmidal Movement Disorders. *Semin Nucl Med.* <https://doi.org/10.1053/j.semnuclmed.2016.09.007>
- Fu, Y., Yang, K., Huang, Y., Zhang, Y., Li, S., Li, W.D., 2022. Deciphering Risperidone-Induced Lipogenesis by Network Pharmacology and Molecular Validation. *Front Psychiatry* 13. <https://doi.org/10.3389/fpsy.2022.870742>
- Fujita, T., Aoki, N., Mori, C., Fujita, E., Matsushima, T., Homma, K.J., Yamaguchi, S., 2022. Serotonergic Neurons in the Chick Brainstem Express Various Serotonin Receptor Subfamily Genes. *Front Physiol* 12. <https://doi.org/10.3389/fphys.2021.815997>
- Fukuyama, K., Motomura, E., Okada, M., 2023. Therapeutic Potential and Limitation of Serotonin Type 7 Receptor Modulation. *Int J Mol Sci.* <https://doi.org/10.3390/ijms24032070>
- Funari, A., Fiscon, G., Paci, P., 2024. Network medicine and systems pharmacology approaches to predicting adverse drug effects. *Br J Pharmacol.* <https://doi.org/10.1111/bph.17330>
- Fyfe, T.J., Kellam, B., Sykes, D.A., Capuano, B., Scammells, P.J., Lane, J.R., Charlton, S.J., Mistry, S.N., 2019. Structure–Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D 2 Receptor. *J Med Chem* 62, 9488–9520. <https://doi.org/10.1021/acs.jmedchem.9b00864>
- Gaitonde, S.A., Avet, C., de la Fuente Revenga, M., Blondel-Tepaz, E., Shahraki, A., Pastor, A.M., Talagayev, V., Robledo, P., Kolb, P., Selent, J., González-Maeso, J., Bouvier, M., 2024. Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT<sub>2A</sub> receptor. *Mol Psychiatry.* <https://doi.org/10.1038/s41380-024-02531-7>
- Galderisi, S., Kaiser, S., Bitter, I., Nordentoft, M., Mucci, A., Sabé, M., Giordano, G.M., Nielsen, M.Ø., Glenthøj, L.B., Pezzella, P., Falkai, P., Dollfus, S., Gaebel, W., 2021. EPA guidance on treatment of negative symptoms in schizophrenia. *European Psychiatry* 64. <https://doi.org/10.1192/j.eurpsy.2021.13>
- Gallo, A., Lapointe, S., Stip, E., Potvin, S., Rompré, P.-P., 2010. Quetiapine blocks cocaine-induced enhancement of brain stimulation reward. *Behavioural Brain Research* 208, 163–168. <https://doi.org/10.1016/j.bbr.2009.11.029>

- Galvan, A., Kuwajima, M., Smith, Y., 2006. Glutamate and GABA receptors and transporters in the basal ganglia: What does their subsynaptic localization reveal about their function? *Neuroscience* 143, 351–375. <https://doi.org/10.1016/j.neuroscience.2006.09.019>
- Ganguly, P., Soliman, A., Moustafa, A.A., 2018. Holistic Management of Schizophrenia Symptoms Using Pharmacological and Non-pharmacological Treatment. *Front Public Health*. <https://doi.org/10.3389/fpubh.2018.00166>
- Gardier, A.M., 2013. Antidepressant activity: contribution of brain microdialysis in knock-out mice to the understanding of BDNF/5-HT transporter/5-HT autoreceptor interactions. *Front Pharmacol* 4. <https://doi.org/10.3389/fphar.2013.00098>
- Gerrard, L.B., Tantirigama, M.L.S., Bekkers, J.M., 2018. Pre- and Postsynaptic Activation of GABAB Receptors Modulates Principal Cell Excitation in the Piriform Cortex. *Front Cell Neurosci* 12. <https://doi.org/10.3389/fncel.2018.00028>
- Ghit, A., Assal, D., Al-Shami, A.S., Hussein, D.E.E., 2021a. GABAA receptors: structure, function, pharmacology, and related disorders. *Journal of Genetic Engineering and Biotechnology* 19, 123. <https://doi.org/10.1186/s43141-021-00224-0>
- Ghit, A., Assal, D., Al-Shami, A.S., Hussein, D.E.E., 2021b. GABAA receptors: structure, function, pharmacology, and related disorders. *J Genet Eng Biotechnol* 19, 123. <https://doi.org/10.1186/s43141-021-00224-0>
- Gianni, G., Pasqualetti, M., 2023. Wiring and Volume Transmission: An Overview of the Dual Modality for Serotonin Neurotransmission. *ACS Chem Neurosci* 14, 4093–4104. <https://doi.org/10.1021/acchemneuro.3c00648>
- Gimeno, A., Ojeda-Montes, M.J., Tomás-Hernández, S., Cereto-Massagué, A., Beltrán-Debón, R., Mulero, M., Pujadas, G., Garcia-Vallvé, S., 2019. The Light and Dark Sides of Virtual Screening: What Is There to Know? *Int J Mol Sci* 20, 1375. <https://doi.org/10.3390/ijms20061375>
- Giuffrida, E., Platania, C.B.M., Lazzara, F., Conti, F., Marcantonio, N., Drago, F., Bucolo, C., 2024. The Identification of New Pharmacological Targets for the Treatment of Glaucoma: A Network Pharmacology Approach. *Pharmaceuticals* 17. <https://doi.org/10.3390/ph17101333>
- Goetz, T., Arslan, A., Wisden, W., Wulff, P., 2007. GABAA receptors: structure and function in the basal ganglia. pp. 21–41. [https://doi.org/10.1016/S0079-6123\(06\)60003-4](https://doi.org/10.1016/S0079-6123(06)60003-4)
- Gong, L., 2018. Application of Biomedical Text Mining, in: *Artificial Intelligence - Emerging Trends and Applications*. InTech. <https://doi.org/10.5772/intechopen.75924>
- Gottlieb, N., Li, T.Y., Young, A.H., Stokes, P.R.A., 2023. The 5-HT7 receptor system as a treatment target for mood and anxiety disorders: A systematic review. *Journal of Psychopharmacology*. <https://doi.org/10.1177/02698811231211228>

- Graves, S.M., Xie, Z., Stout, K.A., Zampese, E., Burbulla, L.F., Shih, J.C., Kondapalli, J., Patriarchi, T., Tian, L., Brichta, L., Greengard, P., Krainc, D., Schumacker, P.T., Surmeier, D.J., 2020. Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain. *Nat Neurosci* 23, 15–20. <https://doi.org/10.1038/s41593-019-0556-3>
- Grinchii, D., Dremencov, E., 2020. Mechanism of action of atypical antipsychotic drugs in mood disorders. *Int J Mol Sci*. <https://doi.org/10.3390/ijms21249532>
- Gromiha, M.M., Nagarajan, R., Selvaraj, S., 2019. Protein Structural Bioinformatics: An Overview, in: *Encyclopedia of Bioinformatics and Computational Biology*. Elsevier, pp. 445–459. <https://doi.org/10.1016/B978-0-12-809633-8.20278-1>
- Haas, L.T., Salazar, S. V., Kostylev, M.A., Um, J.W., Kaufman, A.C., Strittmatter, S.M., 2016. Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer’s disease. *Brain* 139, 526–546. <https://doi.org/10.1093/brain/awv356>
- Harding, S.D., Armstrong, J.F., Faccenda, E., Southan, C., Alexander, S.P.H., Davenport, A.P., Spedding, M., Davies, J.A., 2024. The IUPHAR/BPS Guide to PHARMACOLOGY in 2024. *Nucleic Acids Res* 52, D1438–D1449. <https://doi.org/10.1093/nar/gkad944>
- Hatabi, K., Hirohara, Y., Kushida, Y., Kuroda, Y., Wakao, S., Trosko, J., Dezawa, M., 2022. Inhibition of Gap Junctional Intercellular Communication Upregulates Pluripotency Gene Expression in Endogenous Pluripotent Muse Cells. *Cells* 11, 2701. <https://doi.org/10.3390/cells11172701>
- Hattori-Usami, N., Kaizaki-Mitsumoto, A., Ashino, T., Yamamoto, M., Numazawa, S., 2023. Toxicity manifestations and sex differences due to MARTA olanzapine.
- Heberle, H., Meirelles, G.V., da Silva, F.R., Telles, G.P., Minghim, R., 2015. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. *BMC Bioinformatics* 16, 169. <https://doi.org/10.1186/s12859-015-0611-3>
- Hegeman, D.J., Hong, E.S., Hernández, V.M., Chan, C.S., 2016. The external globus pallidus: progress and perspectives. *European Journal of Neuroscience* 43, 1239–1265. <https://doi.org/10.1111/ejn.13196>
- Hernández, L.F., Obeso, I., 2016. A STOP signal to striatum mediated by globus pallidus: A new loop discovered. *Movement Disorders* 31, 1142–1142. <https://doi.org/10.1002/mds.26648>
- Hopkins, A.L., 2008. Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol* 4, 682–690. <https://doi.org/10.1038/nchembio.118>
- Huang, D.W., Sherman, B.T., Lempicki, R.A., 2009. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 37, 1–13. <https://doi.org/10.1093/nar/gkn923>

- Huang, X., Yang, J., Yang, S., Cao, S., Qin, D., Zhou, Y., Li, X., Ye, Y., Wu, J., 2017. Role of tandospirone, a 5-HT<sub>1A</sub> receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms.
- Iglesias, A., Cimadevila, M., Cadavid, M.I., Loza, M.I., Brea, J., 2017. Serotonin-2A homodimers are needed for signalling via both phospholipase A 2 and phospholipase C in transfected CHO cells. *Eur J Pharmacol* 800, 63–69. <https://doi.org/10.1016/j.ejphar.2017.02.028>
- Im, D., Inoue, A., Fujiwara, T., Nakane, T., Yamanaka, Y., Uemura, T., Mori, C., Shiimura, Y., Kimura, K.T., Asada, H., Nomura, N., Tanaka, T., Yamashita, A., Nango, E., Tono, K., Kadji, F.M.N., Aoki, J., Iwata, S., Shimamura, T., 2020. Structure of the dopamine D2 receptor in complex with the antipsychotic drug spiperone. *Nat Commun* 11, 6442. <https://doi.org/10.1038/s41467-020-20221-0>
- Inazu, M., 2019. Functional Expression of Choline Transporters in the Blood–Brain Barrier. *Nutrients* 11, 2265. <https://doi.org/10.3390/nu11102265>
- Ishii, T., Kimura, Y., Ichise, M., Takahata, K., Kitamura, S., Moriguchi, S., Kubota, M., Zhang, M.R., Yamada, M., Higuchi, M., Okubo, Y., Suhara, T., 2017. Anatomical relationships between serotonin 5-HT<sub>2A</sub> and dopamine D2 receptors in living human brain. *PLoS One* 12. <https://doi.org/10.1371/journal.pone.0189318>
- Johnson, K.A., Mateo, Y., Lovinger, D.M., 2017. Metabotropic glutamate receptor 2 inhibits thalamically-driven glutamate and dopamine release in the dorsal striatum. *Neuropharmacology* 117, 114–123. <https://doi.org/10.1016/j.neuropharm.2017.01.038>
- Joseph, D., Pidathala, S., Mallela, A.K., Penmatsa, A., 2019. Structure and Gating Dynamics of Na<sup>+</sup>/Cl<sup>-</sup> Coupled Neurotransmitter Transporters. *Front Mol Biosci* 6. <https://doi.org/10.3389/fmolb.2019.00080>
- Juncal-Ruiz, M., Ramirez-Bonilla, M., Gomez-Arnau, J., Ortiz-Garcia de la Foz, V., Suarez-Pinilla, P., Martinez-Garcia, O., Neergaard, K.D., Tabares-Seisdedos, R., Crespo-Facorro, B., 2017. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. *Psychopharmacology (Berl)* 234, 2563–2570. <https://doi.org/10.1007/s00213-017-4646-1>
- Kaar, S.J., Natesan, S., McCutcheon, R., Howes, O.D., 2020. Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. *Neuropharmacology* 172, 107704. <https://doi.org/10.1016/j.neuropharm.2019.107704>
- Kajita, Y., Mushiake, H., 2021. Heterogeneous GAD65 Expression in Subtypes of GABAergic Neurons Across Layers of the Cerebral Cortex and Hippocampus. *Front Behav Neurosci* 15. <https://doi.org/10.3389/fnbeh.2021.750869>
- Kanda, Y., Okada, M., Ikarashi, R., Morioka, E., Kondo, T., Ikeda, M., 2016. Bimodal modulation of store-operated Ca<sup>2+</sup> channels by clozapine in astrocytes. *Neurosci Lett* 635, 56–60. <https://doi.org/10.1016/j.neulet.2016.10.027>

- Kang, D.D., Sibille, E., Kaminski, N., Tseng, G.C., 2012. MetaQC: objective quality control and inclusion/exclusion criteria for genomic meta-analysis. *Nucleic Acids Res* 40, e15–e15. <https://doi.org/10.1093/nar/gkr1071>
- KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA, n.d.
- Kesby, J.P., Eyles, D.W., McGrath, J.J., Scott, J.G., 2018. Dopamine, psychosis and schizophrenia: The widening gap between basic and clinical neuroscience. *Transl Psychiatry*. <https://doi.org/10.1038/s41398-017-0071-9>
- Kikuchi, T., Maeda, K., Suzuki, M., Hirose, T., Futamura, T., McQuade, R.D., 2021. Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. *Neuropsychopharmacol Rep* 41, 134–143. <https://doi.org/10.1002/npr2.12180>
- Kim, K., Che, T., Panova, O., DiBerto, J.F., Lyu, J., Krumm, B.E., Wacker, D., Robertson, M.J., Seven, A.B., Nichols, D.E., Shoichet, B.K., Skiniotis, G., Roth, B.L., 2020. Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor. *Cell* 182, 1574-1588.e19. <https://doi.org/10.1016/j.cell.2020.08.024>
- Kim, S.A., 2021. 5-HT1A and 5-HT2A Signaling, Desensitization, and Downregulation: Serotonergic Dysfunction and Abnormal Receptor Density in Schizophrenia and the Prodrome. *Cureus*. <https://doi.org/10.7759/cureus.15811>
- Kim, S.F., Huang, A.S., Snowman, A.M., Teuscher, C., Snyder, S.H., 2007. Antipsychotic drug-induced weight gain mediated by histamine H 1 receptor-linked activation of hypothalamic AMP-kinase.
- Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., Iwata, N., 2021. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. *Mol Psychiatry* 26, 4146–4157. <https://doi.org/10.1038/s41380-020-00946-6>
- Koster, K.P., Sherman, S.M., 2024. Convergence of inputs from the basal ganglia with layer 5 of motor cortex and cerebellum in mouse motor thalamus. *Elife* 13. <https://doi.org/10.7554/eLife.97489>
- Kringelbach, M.L., Cruzat, J., Cabral, J., Knudsen, G.M., Carhart-Harris, R., Whybrow, P.C., Logothetis, N.K., Deco, G., 2020. Dynamic coupling of whole-brain neuronal and neurotransmitter systems. *Proceedings of the National Academy of Sciences* 117, 9566–9576. <https://doi.org/10.1073/pnas.1921475117>
- Kromer, J.A., Bokil, H., Tass, P.A., 2023. Synaptic network structure shapes cortically evoked spatio-temporal responses of STN and GPe neurons in a computational model. *Front Neuroinform* 17. <https://doi.org/10.3389/fninf.2023.1217786>
- Kusumi, I., Boku, S., Takahashi, Y., 2015. Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis. *Psychiatry Clin Neurosci*. <https://doi.org/10.1111/pcn.12242>

- Lai, X., Wang, X., Hu, Y., Su, S., Li, W., Li, S., 2020. Editorial: Network pharmacology and traditional medicine. *Front Pharmacol*.  
<https://doi.org/10.3389/fphar.2020.01194>
- Laikowski, M.M., Reisdorfer, F., Moura, S., 2019. NACHR  $\alpha 4\beta 2$  Subtype and their Relation with Nicotine Addiction, Cognition, Depression and Hyperactivity Disorder. *Curr Med Chem* 26, 3792–3811.  
<https://doi.org/10.2174/0929867325666180410105135>
- Le Merrer, J., Becker, J.A.J., Befort, K., Kieffer, B.L., 2009. Reward processing by the opioid system in the brain. *Physiol Rev* 89, 1379–412.  
<https://doi.org/10.1152/physrev.00005.2009>
- Lee, W.Y., Lee, C.Y., Kim, Y.S., Kim, C.E., 2019. The methodological trends of traditional herbal medicine employing network pharmacology. *Biomolecules* 9.  
<https://doi.org/10.3390/biom9080362>
- Leey, J., Setters, B., Murphy, P., Antimisariis, D., Miles, T., 2009. QUETIAPINE-INDUCED DYSTONIA AND AGITATION IN PARKINSON'S DISEASE WITH DEMENTIA: A CASE REPORT. *J Am Geriatr Soc* 57, 918–919.  
<https://doi.org/10.1111/j.1532-5415.2009.01911.x>
- Li, C., Tian, H., Li, R., Jia, F., Wang, L., Ma, X., Yang, L., Zhang, Q., Zhang, Y., Yao, K., Zhuo, C., 2024. Molecular mechanisms of quetiapine bidirectional regulation of bipolar depression and mania based on network pharmacology and molecular docking: Evidence from computational biology. *J Affect Disord* 355, 528–539.  
<https://doi.org/10.1016/j.jad.2024.03.096>
- Li, L., Yoo, E.-S., Li, X., Wyler, S.C., Chen, X., Wan, R., Arnold, A.G., Birnbaum, S.G., Jia, L., Sohn, J.-W., Liu, C., 2021. The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain. *Journal of Experimental Medicine* 218. <https://doi.org/10.1084/jem.20202484>
- LI, S., ZHANG, B., 2013. Traditional Chinese medicine network pharmacology: theory, methodology and application. *Chin J Nat Med* 11, 110–120.  
[https://doi.org/10.1016/S1875-5364\(13\)60037-0](https://doi.org/10.1016/S1875-5364(13)60037-0)
- Li, Y.-C., Panikker, P., Xing, B., Yang, S.-S., Alexandropoulos, C., McEachern, E.P., Akumuo, R., Zhao, E., Gulchina, Y., Pletnikov, M. V., Urs, N.M., Caron, M.G., Elefant, F., Gao, W.-J., 2020. Deletion of Glycogen Synthase Kinase-3 $\beta$  in D2 Receptor-Positive Neurons Ameliorates Cognitive Impairment via NMDA Receptor-Dependent Synaptic Plasticity. *Biol Psychiatry* 87, 745–755.  
<https://doi.org/10.1016/j.biopsych.2019.10.025>
- Libowitz, M.R., Nurmi, E.L., 2021. The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children. *Front Psychiatry*.  
<https://doi.org/10.3389/fpsy.2021.623681>
- Lim, S.A.O., Kang, U.J., McGehee, D.S., 2014. Striatal cholinergic interneuron regulation and circuit effects. *Front Synaptic Neurosci* 6.  
<https://doi.org/10.3389/fnsyn.2014.00022>

- Llorca, P.-M., Nuss, P., Fakra, É., Alamome, I., Drapier, D., El Hage, W., Jardri, R., Mouchabac, S., Rabbani, M., Simon, N., Vacheron, M.-N., Azorin, J.-M., 2022. Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. *BMC Psychiatry* 22, 364. <https://doi.org/10.1186/s12888-022-04008-9>
- Lohr, K.M., Masoud, S.T., Salahpour, A., Miller, G.W., 2017. Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease. *European Journal of Neuroscience* 45, 20–33. <https://doi.org/10.1111/ejn.13357>
- Lu, C., Zhu, X., Feng, Y., Ao, W., Li, J., Gao, Z., Luo, H., Chen, M., Cai, F., Zhan, S., Li, H., Sun, W., Hu, J., 2023. Atypical antipsychotics antagonize GABAA receptors in the ventral tegmental area GABA neurons to relieve psychotic behaviors. *Mol Psychiatry* 28, 2107–2121. <https://doi.org/10.1038/s41380-023-01982-8>
- Lyon, K.A., Rood, B.D., Wu, L., Senft, R.A., Goodrich, L. V., Dymecki, S.M., 2020. Sex-specific role for dopamine receptor d2 in dorsal raphe serotonergic neuron modulation of defensive acoustic startle and dominance behavior. *eNeuro* 7, 1–23. <https://doi.org/10.1523/ENEURO.0202-20.2020>
- Ma, T.-L., Zhou, Y., Zhang, C.-Y., Gao, Z.-A., Duan, J.-X., 2021. The role and mechanism of  $\beta$ -arrestin2 in signal transduction. *Life Sci* 275, 119364. <https://doi.org/10.1016/j.lfs.2021.119364>
- Maan, J.S., Ershadi, M., Khan, I., Saadabadi, A., 2023. Quetiapine. StatPearls Publishing, Treasure Island (FL).
- Maith, O., Baladron, J., Einhäuser, W., Hamker, F.H., 2023. Exploration behavior after reversals is predicted by STN-GPe synaptic plasticity in a basal ganglia model. *iScience* 26, 106599. <https://doi.org/10.1016/j.isci.2023.106599>
- Malik, J.A., Yaseen, Z., Thotapalli, L., Ahmed, S., Shaikh, M.F., Anwar, S., 2023. Understanding translational research in schizophrenia: A novel insight into animal models. *Mol Biol Rep*. <https://doi.org/10.1007/s11033-023-08241-7>
- Mallet, N., Leblois, A., Maurice, N., Beurrier, C., 2019. Striatal Cholinergic Interneurons: How to Elucidate Their Function in Health and Disease. *Front Pharmacol* 10. <https://doi.org/10.3389/fphar.2019.01488>
- Mao, L.-M., Young, L., Chu, X.-P., Wang, J.Q., 2024. Regulation of Src family kinases by muscarinic acetylcholine receptors in heterologous cells and neurons. *Front Mol Neurosci* 16. <https://doi.org/10.3389/fnmol.2023.1340725>
- Marder, S.R., Umbricht, D., 2023. Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments. *Schizophr Res*. <https://doi.org/10.1016/j.schres.2023.07.010>
- Marsman, A., Mandl, R.C.W., Klomp, D.W.J., Bohlken, M.M., Boer, V.O., Andreychenko, A., Cahn, W., Kahn, R.S., Luijten, P.R., Hulshoff Pol, H.E., 2014. GABA and glutamate in schizophrenia: A 7 T 1H-MRS study. *Neuroimage Clin* 6, 398–407. <https://doi.org/10.1016/j.nicl.2014.10.005>

- Martino, D., Karnik, V., Osland, S., Barnes, T.R.E., Pringsheim, T.M., 2018. Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis. *Canadian Journal of Psychiatry*. <https://doi.org/10.1177/0706743718777392>
- Masiulis, S., Desai, R., Uchański, T., Serna Martin, I., Lavery, D., Karia, D., Malinauskas, T., Zivanov, J., Pardon, E., Kotecha, A., Steyaert, J., Miller, K.W., Aricescu, A.R., 2019. GABAA receptor signalling mechanisms revealed by structural pharmacology. *Nature* 565, 454–459. <https://doi.org/10.1038/s41586-018-0832-5>
- Mauri, M.C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Pace, C. Di, Altamura, A.C., 2014. CLINICAL PHARMACOLOGY OF ATYPICAL ANTIPSYCHOTICS: AN UPDATE, *EXCLI Journal*.
- McCutcheon, R.A., Krystal, J.H., Howes, O.D., 2020. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. *World Psychiatry* 19, 15–33. <https://doi.org/10.1002/wps.20693>
- Meier, A., Söding, J., 2015. Automatic Prediction of Protein 3D Structures by Probabilistic Multi-template Homology Modeling. *PLoS Comput Biol* 11, e1004343. <https://doi.org/10.1371/journal.pcbi.1004343>
- Melka, M.G., Castellani, C.A., Laufer, B.I., Rajakumar, N., O'Reilly, R., Singh, S.M., 2013. Olanzapine induced DNA methylation changes support the dopamine hypothesis of psychosis. *J Mol Psychiatry* 1. <https://doi.org/10.1186/2049-9256-1-19>
- Meng, X., Ma, J., Kang, A.N., Kang, S.Y., Jung, H.W., Park, Y.-K., 2020. A Novel Approach Based on Metabolomics Coupled With Intestinal Flora Analysis and Network Pharmacology to Explain the Mechanisms of Action of Bekhogainsam Decoction in the Improvement of Symptoms of Streptozotocin-Induced Diabetic Nephropathy in Mice. *Front Pharmacol* 11. <https://doi.org/10.3389/fphar.2020.00633>
- Meunier, C.N.J., Chameau, P., Fossier, P.M., 2017. Modulation of Synaptic Plasticity in the Cortex Needs to Understand All the Players. *Front Synaptic Neurosci* 9. <https://doi.org/10.3389/fnsyn.2017.00002>
- Meyer, R., Skov, K., Dhillon, I.K., Olsson, E., Graudal, N.A., Baandrup, L., Jürgens, G., 2023. Onset of Action of Selected Second-Generation Antipsychotics (Pines)—A Systematic Review and Meta-Analyses. *Biomedicines*. <https://doi.org/10.3390/biomedicines11010082>
- Miller, P.S., Aricescu, A.R., 2014. Crystal structure of a human GABAA receptor. *Nature* 512, 270–275. <https://doi.org/10.1038/nature13293>
- Mohr, P., Masopust, J., Kopeček, M., 2022. Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? *Front Psychiatry*. <https://doi.org/10.3389/fpsy.2021.781946>

- Moustafa, A.A., McMullan, R.D., Rostron, B., Hewedi, D.H., Haladjian, H.H., 2017. The thalamus as a relay station and gatekeeper: relevance to brain disorders. *Rev Neurosci* 28, 203–218. <https://doi.org/10.1515/revneuro-2016-0067>
- Muhammed, M.T., Aki-Yalcin, E., 2024. Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery. *Lett Drug Des Discov* 21, 480–495. <https://doi.org/10.2174/1570180819666220922103109>
- Muñoz, A., Lopez-Lopez, A., Labandeira, C.M., Labandeira-Garcia, J.L., 2020. Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA. *Front Neuroanat* 14. <https://doi.org/10.3389/fnana.2020.00026>
- Murthy, M.K., 2025. Molecular pathways linking the serotonin transporters (SERT) to depressive disorder: from mechanisms to treatments. *Neuroscience* 584, 2–31. <https://doi.org/10.1016/j.neuroscience.2025.08.009>
- Murumkar, P.R., Sharma, M.K., Gupta, P., Patel, N.M., Yadav, M.R., 2023. Selection of Suitable Protein Structure from Protein Data Bank: An Important Step in Structure-based Drug Design Studies. *Mini-Reviews in Medicinal Chemistry* 23, 246–264. <https://doi.org/10.2174/1389557522666220512151454>
- Musah, S., 2021. Uncovering SARS-CoV-2 kidney tropism. *Nat Rev Mol Cell Biol* 22, 509–509. <https://doi.org/10.1038/s41580-021-00370-w>
- Muthuramalingam, P., Jeyasri, R., Varadharajan, V., Priya, A., Dhanapal, A.R., Shin, H., Thiruvengadam, M., Ramesh, M., Krishnan, M., Omosimua, R.O., Sathyaseelan, D.D., Venkidasamy, B., 2024. Network pharmacology: an efficient but underutilized approach in oral, head and neck cancer therapy—a review. *Front Pharmacol*. <https://doi.org/10.3389/fphar.2024.1410942>
- Nagatsu, T., Nakashima, A., Ichinose, H., Kobayashi, K., 2019. Human tyrosine hydroxylase in Parkinson’s disease and in related disorders. *J Neural Transm* 126, 397–409. <https://doi.org/10.1007/s00702-018-1903-3>
- Nambu, A., Chiken, S., 2024. External segment of the globus pallidus in health and disease: Its interactions with the striatum and subthalamic nucleus. *Neurobiol Dis* 190, 106362. <https://doi.org/10.1016/j.nbd.2023.106362>
- Naylor, D.E., Liu, H., Wasterlain, C.G., 2005. Trafficking of GABA A Receptors, Loss of Inhibition, and a Mechanism for Pharmacoresistance in Status Epilepticus. *The Journal of Neuroscience* 25, 7724–7733. <https://doi.org/10.1523/JNEUROSCI.4944-04.2005>
- Nedic Erjavec, G., Grubor, M., Zivkovic, M., Bozina, N., Sagud, M., Nikolac Perkovic, M., Mihaljevic-Peles, A., Pivac, N., Svob Strac, D., 2022a. SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism. *Biomedicines* 10, 3237. <https://doi.org/10.3390/biomedicines10123237>
- Nedic Erjavec, G., Tudor, L., Nikolac Perkovic, M., Podobnik, J., Dodig Curkovic, K., Curkovic, M., Svob Strac, D., Cusek, M., Bortolato, M., Pivac, N., 2022b. Serotonin

5-HT<sub>2A</sub> receptor polymorphisms are associated with irritability and aggression in conduct disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 117, 110542. <https://doi.org/10.1016/j.pnpbp.2022.110542>

Nepal, B., Das, S., Reith, M.E., Kortagere, S., 2023. Overview of the structure and function of the dopamine transporter and its protein interactions. *Front Physiol* 14. <https://doi.org/10.3389/fphys.2023.1150355>

Nguyen, M., Wong, Y.C., Ysselstein, D., Severino, A., Krainc, D., 2019. Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease. *Trends Neurosci* 42, 140–149. <https://doi.org/10.1016/j.tins.2018.11.001>

Nickel, J., Gohlke, B.-O., Erehman, J., Banerjee, P., Rong, W.W., Goede, A., Dunkel, M., Preissner, R., 2014. SuperPred: update on drug classification and target prediction. *Nucleic Acids Res* 42, W26-31. <https://doi.org/10.1093/nar/gku477>

Nikolaus, S., Wittsack, H.-J., Antke, C., Beu, M., Hautzel, H., Decheva, C., Mamlins, E., Mori, Y., Huston, J.P., Antoch, G., Müller, H.-W., 2021. Serotonergic Modulation of Nigrostriatal and Mesolimbic Dopamine and Motor/Exploratory Behaviors in the Rat. *Front Neurosci* 15. <https://doi.org/10.3389/fnins.2021.682398>

NIMH, 2024. Schizophrenia [WWW Document]. URL <https://www.nimh.nih.gov/health/topics/schizophrenia> (accessed 11.27.24).

Noor, F., Qamar, M.T.U., Ashfaq, U.A., Albutti, A., Alwashmi, A.S.S., Aljasir, M.A., 2022. Network Pharmacology Approach for Medicinal Plants: Review and Assessment. *Pharmaceuticals*. <https://doi.org/10.3390/ph15050572>

Nuñez, N.A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M.G., Prokop, L.J., Veldic, M., Seshadri, A., Biernacka, J.M., Frye, M.A., Wang, Z., Singh, B., 2022. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. *J Affect Disord*. <https://doi.org/10.1016/j.jad.2021.12.134>

Ogelman, R., Gomez Wulschner, L.E., Hoelscher, V.M., Hwang, I.-W., Chang, V.N., Oh, W.C., 2024. Serotonin modulates excitatory synapse maturation in the developing prefrontal cortex. *Nat Commun* 15, 1368. <https://doi.org/10.1038/s41467-024-45734-w>

Ohno, Y., Kunisawa, N., Shimizu, S., 2019. Antipsychotic treatment of behavioral and psychological symptoms of dementia (BPSD): Management of extrapyramidal side effects. *Front Pharmacol*. <https://doi.org/10.3389/fphar.2019.01045>

Ohno, Y., Shimizu, S., Tokudome, K., 2013. Pathophysiological Roles of Serotonergic System in Regulating Extrapyramidal Motor Functions. *Biol Pharm Bull* 36, 1396–1400. <https://doi.org/10.1248/bpb.b13-00310>

Okada, M., Fukuyama, K., Motomura, E., 2022. Dose-Dependent Biphasic Action of Quetiapine on AMPK Signalling via 5-HT<sub>7</sub> Receptor: Exploring Pathophysiology of Clinical and Adverse Effects of Quetiapine. *Int J Mol Sci* 23, 9103. <https://doi.org/10.3390/ijms23169103>

- Orsolini, L., Pompili, S., Volpe, U., 2022. Schizophrenia: A Narrative Review of Etiopathogenetic, Diagnostic and Treatment Aspects. *J Clin Med* 11. <https://doi.org/10.3390/jcm11175040>
- Orzelska-Górka, J., Mikulska, J., Wiszniewska, A., Biała, G., 2022a. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. *Int J Mol Sci*. <https://doi.org/10.3390/ijms231810624>
- Orzelska-Górka, J., Mikulska, J., Wiszniewska, A., Biała, G., 2022b. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. *Int J Mol Sci*. <https://doi.org/10.3390/ijms231810624>
- Østerbø, T.B., On, D.M., Oliveras, I., Río-Álamos, C., Sanchez-Gonzalez, A., Tapias-Espinosa, C., Tobeña, A., González-Maeso, J., Fernández-Teruel, A., Aznar, S., 2020. Metabotropic Glutamate Receptor 2 and Dopamine Receptor 2 Gene Expression Predict Sensorimotor Gating Response in the Genetically Heterogeneous NIH-HS Rat Strain. *Mol Neurobiol* 57, 1516–1528. <https://doi.org/10.1007/s12035-019-01829-w>
- Otasek, D., Morris, J.H., Bouças, J., Pico, A.R., Demchak, B., 2019. Cytoscape Automation: empowering workflow-based network analysis. *Genome Biol* 20, 185. <https://doi.org/10.1186/s13059-019-1758-4>
- Otsuka Pharmaceutical, 2014. Aripiprazole Intramuscular Depot - Clinical Summary for Protocol 31-12-291.
- Pal, M.M., 2021. Glutamate: The Master Neurotransmitter and Its Implications in Chronic Stress and Mood Disorders. *Front Hum Neurosci* 15. <https://doi.org/10.3389/fnhum.2021.722323>
- Papp, M., Gruca, P., Lason, M., Litwa, E., Newman-Tancredi, A., Depoortère, R., 2023. The 5-HT<sub>1A</sub> receptor biased agonists, NLX-204 and NLX-101, display ketamine-like RAAD and anti-TRD activities in rat CMS models. *Psychopharmacology (Berl)* 240, 2419–2433. <https://doi.org/10.1007/s00213-023-06389-5>
- Park, S., Kim, Y., Lee, J., Lee, J.Y., Kim, H., Lee, S., Oh, C.-M., 2021. A Systems Biology Approach to Investigating the Interaction between Serotonin Synthesis by Tryptophan Hydroxylase and the Metabolic Homeostasis. *Int J Mol Sci* 22, 2452. <https://doi.org/10.3390/ijms22052452>
- Paul, S.M., Yohn, S.E., Brannan, S.K., Neugebauer, N.M., Breier, A., 2024. Muscarinic Receptor Activators as Novel Treatments for Schizophrenia. *Biol Psychiatry*. <https://doi.org/10.1016/j.biopsych.2024.03.014>
- Pehrson, A.L., Sanchez, C., 2014. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. *CNS Spectr* 19, 121–133. <https://doi.org/10.1017/S1092852913000540>
- Perez, D.M., 2020.  $\alpha$ 1-Adrenergic Receptors in Neurotransmission, Synaptic Plasticity, and Cognition. *Front Pharmacol* 11, 581098. <https://doi.org/10.3389/fphar.2020.581098>

- Perez, X.A., Bordia, T., Quik, M., 2018. The striatal cholinergic system in l-dopa-induced dyskinesias. *J Neural Transm* 125, 1251–1262. <https://doi.org/10.1007/s00702-018-1845-9>
- Peters, S.K., Dunlop, K., Downar, J., 2016. Cortico-Striatal-Thalamic Loop Circuits of the Salience Network: A Central Pathway in Psychiatric Disease and Treatment. *Front Syst Neurosci* 10. <https://doi.org/10.3389/fnsys.2016.00104>
- Piñero, J., Ramírez-Anguita, J.M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., Furlong, L.I., 2019. The DisGeNET knowledge platform for disease genomics: 2019 update. *Nucleic Acids Res*. <https://doi.org/10.1093/nar/gkz1021>
- Pourmirbabaei, S., Dolatshahi, M., Rahmani, F., 2019. Pathophysiological clues to therapeutic applications of glutamate mGlu5 receptor antagonists in levodopa-induced dyskinesia. *Eur J Pharmacol* 855, 149–159. <https://doi.org/10.1016/j.ejphar.2019.05.004>
- Pringsheim, T., Doja, A., Med, M.D., Belanger, S., Patten, S., 2011. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth, *Paediatr Child Health*.
- Qiu, Y., Wang, Y., Wang, X., Wang, C., Xia, Z., 2018. Role of the hippocampal 5-HT1A receptor-mediated cAMP/PKA signalling pathway in sevoflurane-induced cognitivedysfunction in aged rats. *Journal of International Medical Research* 46, 1073–1085. <https://doi.org/10.1177/0300060517744037>
- Raedler, T., 2000. In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia. *Neuropsychopharmacology* 23, 56–68. [https://doi.org/10.1016/S0893-133X\(99\)00162-1](https://doi.org/10.1016/S0893-133X(99)00162-1)
- Rami, F.Z., Nguyen, T.B., Oh, Y.-E., Karamikheirabad, M., Le, T.-H., Chung, Y.-C., 2022. Risperidone Induced DNA Methylation Changes in Dopamine Receptor and Stathmin Genes in Mice Exposed to Social Defeat Stress. *Clinical Psychopharmacology and Neuroscience* 20, 373–388. <https://doi.org/10.9758/cpn.2022.20.2.373>
- Rangel-Barajas, C., Rebec, G. V., 2016. Dysregulation of Corticostriatal Connectivity in Huntington’s Disease: A Role for Dopamine Modulation. *J Huntingtons Dis* 5, 303–331. <https://doi.org/10.3233/JHD-160221>
- Rao, M.S., Gupta, R., Liguori, M.J., Hu, M., Huang, X., Mantena, S.R., Mittelstadt, S.W., Blomme, E.A.G., Van Vleet, T.R., 2019. Novel Computational Approach to Predict Off-Target Interactions for Small Molecules. *Front Big Data* 2. <https://doi.org/10.3389/fdata.2019.00025>
- Rappaport, N., Twik, M., Plaschkes, I., Nudel, R., Iny Stein, T., Levitt, J., Gershoni, M., Morrey, C.P., Safran, M., Lancet, D., 2017. MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search. *Nucleic Acids Res* 45, D877–D887. <https://doi.org/10.1093/nar/gkw1012>

- Reiner, A., Levitz, J., 2018. Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert. *Neuron* 98, 1080–1098. <https://doi.org/10.1016/j.neuron.2018.05.018>
- Reynolds de Sousa, T., Ribeiro, M., Novais, F., 2024. Assessment of Innovative Pharmacological Targets in Schizophrenia. *Curr Treat Options Psychiatry*. <https://doi.org/10.1007/s40501-024-00324-x>
- Ricci, V., De Berardis, D., Maina, G., 2024. Third-Generation Antipsychotics and Lurasidone in the Treatment of Substance-Induced Psychoses: A Narrative Review. *Healthcare (Switzerland)*. <https://doi.org/10.3390/healthcare12030339>
- Rodriguez-Esteban, R., 2009. Biomedical Text Mining and Its Applications. *PLoS Comput Biol* 5, e1000597. <https://doi.org/10.1371/journal.pcbi.1000597>
- Rok-Bujko, P., 2022. Molecular mechanisms of antipsychotics – their influence on intracellular signaling pathways, and epigenetic and post-transcription processes. *Postępy Psychiatrii i Neurologii* 31, 74–84. <https://doi.org/10.5114/ppn.2022.117963>
- Rybakowski, J.K., 2023. Application of Antipsychotic Drugs in Mood Disorders. *Brain Sci*. <https://doi.org/10.3390/brainsci13030414>
- Sahlholm, K., Zeberg, H., Nilsson, J., Ögren, S.O., Fuxe, K., Århem, P., 2016a. The fast-off hypothesis revisited: A functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor. *European Neuropsychopharmacology* 26, 467–476. <https://doi.org/10.1016/j.euroneuro.2016.01.001>
- Sahlholm, K., Zeberg, H., Nilsson, J., Ögren, S.O., Fuxe, K., Århem, P., 2016b. The fast-off hypothesis revisited: A functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor. *European Neuropsychopharmacology* 26, 467–476. <https://doi.org/10.1016/j.euroneuro.2016.01.001>
- Sánchez-Soto, M., Boldizar, N.M., Schardien, K.A., Madaras, N.S., Willette, B.K.A., Inbody, L.R., Dasaro, C., Moritz, A.E., Drube, J., Haider, R.S., Free, R.B., Hoffman, C., Sibley, D.R., 2023. G Protein-Coupled Receptor Kinase 2 Selectively Enhances  $\beta$ -Arrestin Recruitment to the D2 Dopamine Receptor through Mechanisms That Are Independent of Receptor Phosphorylation. *Biomolecules* 13, 1552. <https://doi.org/10.3390/biom13101552>
- Sanchez-Vives, M. V., Barbero-Castillo, A., Perez-Zabalza, M., Reig, R., 2021. GABAB receptors: modulation of thalamocortical dynamics and synaptic plasticity. *Neuroscience* 456, 131–142. <https://doi.org/10.1016/j.neuroscience.2020.03.011>
- Sayers, E.W., Bolton, E.E., Brister, J.R., Canese, K., Chan, J., Comeau, D.C., Connor, R., Funk, K., Kelly, C., Kim, S., Madej, T., Marchler-Bauer, A., Lanczycki, C., Lathrop, S., Lu, Z., Thibaud-Nissen, F., Murphy, T., Phan, L., Skripchenko, Y., Tse, T., Wang, J., Williams, R., Trawick, B.W., Pruitt, K.D., Sherry, S.T., 2022. Database resources of the national center for biotechnology information. *Nucleic Acids Res* 50, D20–D26. <https://doi.org/10.1093/nar/gkab1112>

- Schoretsanitis, G., Haen, E., Hiemke, C., Grönder, G., Stegmann, B., Schruers, K.R.J., Veselinovic, T., Lammertz, S.E., Paulzen, M., 2016. Risperidone-induced extrapyramidal side effects: Is the need for anticholinergics the consequence of high plasma concentrations? *Int Clin Psychopharmacol* 31, 259–264. <https://doi.org/10.1097/YIC.000000000000131>
- Schuller, H.M., 2017. A new twist to neurotransmitter receptors and cancer. *J Cancer Metastasis Treat* 3, 71. <https://doi.org/10.20517/2394-4722.2017.18>
- Seeman, M. V, 2021. History of the dopamine hypothesis of antipsychotic action. *World J Psychiatry* 11, 355–364. <https://doi.org/10.5498/wjp.v11.i7.355>
- Selvan, P., Devkare, P., Shetty, A., Dharmadhikari, S., Khandhedha, C., Mane, A., Mehta, S., Andrade, C., 2024. A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia. *Front Psychiatry*. <https://doi.org/10.3389/fpsy.2024.1385925>
- Shah, R., Grover, S., Maheshwari, U., Kate, N., Malhotra, N., 2010. Acute akathisia with quetiapine: A case report and review of literature. *Indian J Pharmacol* 42, 416. <https://doi.org/10.4103/0253-7613.71896>
- Shapiro, D.A., Renock, S., Arrington, E., Chiodo, L.A., Liu, L.-X., Sibley, D.R., Roth, B.L., Mailman, R., 2003. Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology. *Neuropsychopharmacology* 28, 1400–1411. <https://doi.org/10.1038/sj.npp.1300203>
- Shaye, H., Stauch, B., Gati, C., Cherezov, V., 2021. Molecular mechanisms of metabotropic GABA B receptor function. *Sci Adv* 7. <https://doi.org/10.1126/sciadv.abg3362>
- Shin, H.W., Chung, S.J., 2012. Drug-Induced parkinsonism. *Journal of Clinical Neurology (Korea)* 8, 15–21. <https://doi.org/10.3988/jcn.2012.8.1.15>
- Shrivastava, A., Kumar, J., 2016. In-Silico Assessment of Various PDB Entries of Pflhdh Enzyme for their Use in SBDD. *Chemical Informatics* 2. <https://doi.org/10.21767/2470-6973.100016>
- Siafis, S., Tzachanis, D., Samara, M., Papazisis, G., 2018. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. *Curr Neuropharmacol* 16, 1210–1223. <https://doi.org/10.2174/1570159X15666170630163616>
- Siafis, S., Wu, H., Wang, D., Burschinski, A., Nomura, N., Takeuchi, H., Schneider-Thoma, J., Davis, J.M., Leucht, S., 2023. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. *Mol Psychiatry* 28, 3267–3277. <https://doi.org/10.1038/s41380-023-02203-y>
- Sigel, E., Steinmann, M.E., 2012. Structure, Function, and Modulation of GABAA Receptors. *Journal of Biological Chemistry* 287, 40224–40231. <https://doi.org/10.1074/jbc.R112.386664>

- Simpson, G.M., Lindenmayer, J.-P., 1997. Extrapiramidal Symptoms in Patients Treated With Risperidone. *J Clin Psychopharmacol* 17, 194–201. <https://doi.org/10.1097/00004714-199706000-00010>
- Sinenko, S.A., Kuzmin, A.A., Skvortsova, E. V., Ponomartsev, S. V., Efimova, E. V., Bader, M., Alenina, N., Tomilin, A.N., 2023. Tryptophan Hydroxylase-2-Mediated Serotonin Biosynthesis Suppresses Cell Reprogramming into Pluripotent State. *Int J Mol Sci* 24, 4862. <https://doi.org/10.3390/ijms24054862>
- Sintia P, D., Suratini, S., Biruni, M.Z., Kurniasih, N., Helmi, R., Subarti, D., Nur'aeni, Viaza, E., Adriany, Jerubu, B.D., Machdiawati, R., Jasmine, N., Kamal, A.Z., Ayunovani F, M., 2021. *Pedoman Pelayanan Kefarmasian Pada Pasien Gangguan Jiwa*, 1st ed. Kementerian Kesehatan RI, Jakarta.
- Song, Y.-N., Xia, S., Sun, Z., Chen, Y.-C., Jiao, L., Wan, W.-H., Zhang, H.-W., Guo, X., Guo, H., Jia, S.-F., Li, X.-X., Cao, S.-X., Fu, L.-B., Liu, M.-M., Zhou, T., Zhang, L.-F., Jia, Q.-Q., 2025. Metabolic pathway modulation by olanzapine: Multitarget approach for treating violent aggression in patients with schizophrenia. *World J Psychiatry* 15. <https://doi.org/10.5498/wjp.v15.i1.101186>
- Soraya, G.V., Ulhaq, Z.S., Shodry, S., A'raaf Sirojan Kusuma, M., Herawangsa, S., Sativa, M.O., Gustaf, A., Faridwazdi, D.A.N., Florentia, S.W., Raisa, N., Bintang, A.K., Akbar, M., 2022. Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis. *Neurological Sciences* 43, 3649–3670. <https://doi.org/10.1007/s10072-021-05829-4>
- Spiros, A., Roberts, P., Geerts, H., 2017. Semi-mechanistic computer simulation of psychotic symptoms in schizophrenia with a model of a humanized cortico-striatal-thalamocortical loop. *European Neuropsychopharmacology* 27, 107–119. <https://doi.org/10.1016/j.euroneuro.2016.12.006>
- Stahl, S.M., 2018. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: Dopamine, serotonin, and glutamate. *CNS Spectr* 23, 187–191. <https://doi.org/10.1017/S1092852918001013>
- Stark, A.D., Jordan, S., Allers, K.A., Bertekap, R.L., Chen, R., Mistry Kannan, T., Molski, T.F., Yocca, F.D., Sharp, T., Kikuchi, T., Burris, K.D., 2007. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies. *Psychopharmacology (Berl)* 190, 373–382. <https://doi.org/10.1007/s00213-006-0621-y>
- Stauch, B., Johansson, L.C., McCorvy, J.D., Patel, N., Han, G.W., Huang, X.-P., Gati, C., Batyuk, A., Slocum, S.T., Ishchenko, A., Brehm, W., White, T.A., Michaelian, N., Madsen, C., Zhu, L., Grant, T.D., Grandner, J.M., Shiriaeva, A., Olsen, R.H.J., Tribo, A.R., Yous, S., Stevens, R.C., Weierstall, U., Katritch, V., Roth, B.L., Liu, W., Cherezov, V., 2019. Structural basis of ligand recognition at the human MT1 melatonin receptor. *Nature* 569, 284–288. <https://doi.org/10.1038/s41586-019-1141-3>

- Štrac, D.Š., Pivac, N., Mück-Šeler, D., 2016. The serotonergic system and cognitive function. *Transl Neurosci*. <https://doi.org/10.1515/tnsci-2016-0007>
- Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., Mao, F., 2024. Cell–cell communication: new insights and clinical implications. *Signal Transduct Target Ther* 9, 196. <https://doi.org/10.1038/s41392-024-01888-z>
- Sullivan, L., Clarke, W., Berg, K., 2015. Atypical antipsychotics and inverse agonism at 5-HT<sub>2</sub> receptors. *Curr Pharm Des* 21, 3732–3738. <https://doi.org/10.2174/1381612821666150605111236>
- Sun, B., Feng, D., Chu, M.L.-H., Fish, I., Lovera, S., Sands, Z.A., Kelm, S., Valade, A., Wood, M., Ceska, T., Kobilka, T.S., Lebon, F., Kobilka, B.K., 2021. Crystal structure of dopamine D1 receptor in complex with G protein and a non-catechol agonist. *Nat Commun* 12, 3305. <https://doi.org/10.1038/s41467-021-23519-9>
- Sykes, D.A., Moore, H., Stott, L., Holliday, N., Javitch, J.A., Robert Lane, J., Charlton, S.J., 2017. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. *Nat Commun* 8. <https://doi.org/10.1038/s41467-017-00716-z>
- Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A.L., Fang, T., Doncheva, N.T., Pyysalo, S., Bork, P., Jensen, L.J., von Mering, C., 2023. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res* 51, D638–D646. <https://doi.org/10.1093/nar/gkac1000>
- Szota, A.M., Scheel-Krüger, J., 2020. The role of glutamate receptors and their interactions with dopamine and other neurotransmitters in the development of tardive dyskinesia: preclinical and clinical results. *Behavioural Pharmacology* 31, 511–523. <https://doi.org/10.1097/FBP.0000000000000563>
- Taddeucci, A., Olivero, G., Roggeri, A., Milanese, C., Giorgio, F.P. Di, Grilli, M., Marchi, M., Garrone, B., Pittaluga, A., 2022. Presynaptic 5-HT<sub>2A</sub>-mGlu<sub>2/3</sub> Receptor–Receptor Crosstalk in the Prefrontal Cortex: Metamodulation of Glutamate Exocytosis. *Cells* 11, 3035. <https://doi.org/10.3390/cells11193035>
- Takekita, Y., Fabbri, C., Kato, M., Koshikawa, Y., Tajika, A., Kinoshita, T., Serretti, A., 2016. HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. *International Journal of Neuropsychopharmacology* 19, pyv125. <https://doi.org/10.1093/ijnp/pyv125>
- Tan, Y.-Y., Jenner, P., Chen, S.-D., 2022. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future. *J Parkinsons Dis* 12, 477–493. <https://doi.org/10.3233/JPD-212976>
- Tang, Y., Li, M., Wang, J., Pan, Y., Wu, F.X., 2015. CytoNCA: A cytoscape plugin for centrality analysis and evaluation of protein interaction networks. *BioSystems* 127, 67–72. <https://doi.org/10.1016/j.biosystems.2014.11.005>

- Terkelsen, M.H., Hvingelby, V.S., Pavese, N., 2022. Molecular Imaging of the GABAergic System in Parkinson's Disease and Atypical Parkinsonisms. *Curr Neurol Neurosci Rep* 22, 867–879. <https://doi.org/10.1007/s11910-022-01245-z>
- TERUNUMA, M., 2018. Diversity of structure and function of GABA<sub>A</sub> receptors: a complexity of GABA<sub>A</sub>-mediated signaling. *Proceedings of the Japan Academy, Series B* 94, 390–411. <https://doi.org/10.2183/pjab.94.026>
- Thomson, S.R., Chogtu, B., Bhattacharjee, D., Agarwal, S., 2017. Extrapyramidal symptoms probably related to risperidone treatment: A case series. *Ann Neurosci* 24, 155–163. <https://doi.org/10.1159/000477153>
- Tretter, E.V., 2008. GABAA receptor dynamics and constructing GABAergic synapses. *Front Mol Neurosci* 1. <https://doi.org/10.3389/neuro.02.007.2008>
- Trimble, E.A., Kell, P.A., Avella, M.A., France, C.R., Rhudy, J.L., 2024. Opioid Receptor Mu 1 Gene (OPRM1) A118G Polymorphism and Emotional Modulation of Pain. *J Pain Res* 17, 489–500. <https://doi.org/10.2147/JPR.S442431>
- Truong, T.T.T., Bortolasci, C.C., Kidnapillai, S., Spolding, B., Panizzutti, B., Liu, Z.S.J., Kim, J.H., Dean, O.M., Richardson, M.F., Berk, M., Walder, K., 2022. Integrative Analyses of Transcriptomes to Explore Common Molecular Effects of Antipsychotic Drugs. *Int J Mol Sci* 23, 7508. <https://doi.org/10.3390/ijms23147508>
- Tsermpini, E.E., Redenšek, S., Dolžan, V., 2022. Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies. *Front Pharmacol* 12. <https://doi.org/10.3389/fphar.2021.834129>
- Uhl, G.R., 2019. Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities. *Ann Clin Transl Neurol* 6, 406–415. <https://doi.org/10.1002/acn3.707>
- Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., Wernerus, H., Björling, L., Ponten, F., 2010. Towards a knowledge-based Human Protein Atlas. *Nat Biotechnol* 28, 1248–1250. <https://doi.org/10.1038/nbt1210-1248>
- Urban, J.D., Clarke, W.P., von Zastrow, M., Nichols, D.E., Kobilka, B., Weinstein, H., Javitch, J.A., Roth, B.L., Christopoulos, A., Sexton, P.M., Miller, K.J., Spedding, M., Mailman, R.B., 2007. Functional Selectivity and Classical Concepts of Quantitative Pharmacology. *J Pharmacol Exp Ther* 320, 1–13. <https://doi.org/10.1124/jpet.106.104463>
- Urs, N.M., Peterson, S.M., Caron, M.G., 2017. New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy. *Biol Psychiatry*. <https://doi.org/10.1016/j.biopsych.2016.10.011>
- Vaiman, E.E., Shnayder, N.A., Khasanova, A.K., Strel'nik, A.I., Gayduk, A.J., Al-Zamil, M., Sapronova, M.R., Zhukova, N.G., Smirnova, D.A., Nasyrova, R.F., 2022.

Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism.  
Biomedicines. <https://doi.org/10.3390/biomedicines10082010>

Vaiman, E.E., Shnayder, N.A., Novitsky, M.A., Dobrodeeva, V.S., Goncharova, P.S., Bochanova, E.N., Sapronova, M.R., Popova, T.E., Tappakhov, A.A., Nasyrova, R.F., 2021. Candidate genes encoding dopamine receptors as predictors of the risk of antipsychotic-induced parkinsonism and tardive dyskinesia in schizophrenic patients. *Biomedicines* 9. <https://doi.org/10.3390/biomedicines9080879>

Valli, M., Cho, S.S., Uribe, C., Masellis, M., Chen, R., Mihaescu, A., Strafella, A.P., 2021. VMAT2 availability in Parkinson's disease with probable REM sleep behaviour disorder. *Mol Brain* 14, 165. <https://doi.org/10.1186/s13041-021-00875-7>

Van Drunen, R., Eckel-Mahan, K., 2023. Circadian rhythms as modulators of brain health during development and throughout aging. *Front Neural Circuits* 16. <https://doi.org/10.3389/fncir.2022.1059229>

Vaughan, R.A., Foster, J.D., 2013. Mechanisms of dopamine transporter regulation in normal and disease states. *Trends Pharmacol Sci* 34, 489–96. <https://doi.org/10.1016/j.tips.2013.07.005>

Wallach, J., Cao, A.B., Calkins, M.M., Heim, A.J., Lanham, J.K., Bonniwell, E.M., Hennessey, J.J., Bock, H.A., Anderson, E.I., Sherwood, A.M., Morris, H., de Klein, R., Klein, A.K., Cuccurazzu, B., Gamrat, J., Fannana, T., Zauhar, R., Halberstadt, A.L., McCorvy, J.D., 2023a. Identification of 5-HT<sub>2A</sub> receptor signaling pathways associated with psychedelic potential. *Nat Commun* 14, 8221. <https://doi.org/10.1038/s41467-023-44016-1>

Wallach, J., Cao, A.B., Calkins, M.M., Heim, A.J., Lanham, J.K., Bonniwell, E.M., Hennessey, J.J., Bock, H.A., Anderson, E.I., Sherwood, A.M., Morris, H., de Klein, R., Klein, A.K., Cuccurazzu, B., Gamrat, J., Fannana, T., Zauhar, R., Halberstadt, A.L., McCorvy, J.D., 2023b. Identification of 5-HT<sub>2A</sub> receptor signaling pathways associated with psychedelic potential. *Nat Commun* 14, 8221. <https://doi.org/10.1038/s41467-023-44016-1>

Wang, G., Zhu, W., 2016. Molecular Docking for Drug Discovery and Development: A Widely Used Approach but Far from Perfect. *Future Med Chem* 8, 1707–1710. <https://doi.org/10.4155/fmc-2016-0143>

Wang, K.H., Penmatsa, A., Gouaux, E., 2015. Neurotransmitter and psychostimulant recognition by the dopamine transporter. *Nature* 521, 322–327. <https://doi.org/10.1038/nature14431>

Wang, S., Che, T., Levit, A., Shoichet, B.K., Wacker, D., Roth, B.L., 2018. Structure of the D<sub>2</sub> dopamine receptor bound to the atypical antipsychotic drug risperidone. *Nature* 555, 269–273. <https://doi.org/10.1038/nature25758>

Wei, C.-H., Kao, H.-Y., Lu, Z., 2013. PubTator: a web-based text mining tool for assisting biocuration. *Nucleic Acids Res* 41, W518–W522. <https://doi.org/10.1093/nar/gkt441>

Weinstein, J.J., Chohan, M.O., Slifstein, M., Kegeles, L.S., Moore, H., Abi-Dargham, A., 2017. Pathway-Specific Dopamine Abnormalities in Schizophrenia. *Biol Psychiatry*. <https://doi.org/10.1016/j.biopsych.2016.03.2104>

WHO, 2025. VigiAccess [WWW Document]. URL <https://www.vigiaccess.org/> (accessed 2.16.25).

WHO, 2024. Clozapine [WWW Document]. 2024. URL <https://www.vigiaccess.org/> (accessed 12.9.24).

Wischof, L., Koch, M., 2016. 5-HT<sub>2A</sub> and mGlu<sub>2/3</sub> receptor interactions. *Behavioural Pharmacology* 27, 1–11. <https://doi.org/10.1097/FBP.0000000000000183>

Wisidagama, S., Selladurai, A., Wu, P., Isetta, M., Serra-Mestres, J., 2021. Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review. *Medicines* 8, 24. <https://doi.org/10.3390/medicines8060024>

Wu, H.-H., Choi, S., Levitt, P., 2016. Differential patterning of genes involved in serotonin metabolism and transport in extra-embryonic tissues of the mouse. *Placenta* 42, 74–83. <https://doi.org/10.1016/j.placenta.2016.03.013>

Wu, J., Li, X.-Y., Liang, J., Xie, J., Deng, C.-N., Chen, Z.-J., Lai, C.-S., Yang, Z.-J., 2022. Network pharmacological analysis of active components of Tongqiao Huoxue Decoction in the treatment of intracerebral hemorrhage. *Ann Transl Med* 10, 567–567. <https://doi.org/10.21037/atm-22-1403>

Wu, Q., Wang, X., Wang, Y., Long, Y.J., Zhao, J.P., Wu, R.R., 2021. Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia. *Neurosci Bull*. <https://doi.org/10.1007/s12264-021-00740-6>

Xiao, C., Ji, Y., Luan, Y., Jia, T., Yin, C., Zhou, C., 2022. Differential modulation of subthalamic projection neurons by short-term and long-term electrical stimulation in physiological and parkinsonian conditions. *Acta Pharmacol Sin* 43, 1928–1939. <https://doi.org/10.1038/s41401-021-00811-4>

Xing, L., Kalebic, N., Namba, T., Vaid, S., Wimberger, P., Huttner, W.B., 2020. Serotonin Receptor 2A Activation Promotes Evolutionarily Relevant Basal Progenitor Proliferation in the Developing Neocortex. *Neuron* 108, 1113–1129.e6. <https://doi.org/10.1016/j.neuron.2020.09.034>

Xu, H., Yang, F., 2022. The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia. *Transl Psychiatry* 12, 464. <https://doi.org/10.1038/s41398-022-02233-0>

Yao, Z.-J., Dong, J., Che, Y.-J., Zhu, M.-F., Wen, M., Wang, N.-N., Wang, S., Lu, A.-P., Cao, D.-S., 2016. TargetNet: a web service for predicting potential drug–target interaction profiling via multi-target SAR models. *J Comput Aided Mol Des* 30, 413–424. <https://doi.org/10.1007/s10822-016-9915-2>

Zhang, G., Stackman, R.W., 2015. The role of serotonin 5-HT<sub>2A</sub> receptors in memory and cognition. *Front Pharmacol*. <https://doi.org/10.3389/fphar.2015.00225>

- Zhang, R., Zhu, X., Bai, H., Ning, K., 2019. Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment. *Front Pharmacol* 10. <https://doi.org/10.3389/fphar.2019.00123>
- Zhang, Z., Zhang, S., Fu, P., Zhang, Zhang, Lin, K., Ko, J.K.-S., Yung, K.K.-L., 2019. Roles of Glutamate Receptors in Parkinson's Disease. *Int J Mol Sci* 20. <https://doi.org/10.3390/ijms20184391>
- Zhu, S., Noviello, C.M., Teng, J., Walsh, R.M., Kim, J.J., Hibbs, R.E., 2018. Structure of a human synaptic GABAA receptor. *Nature* 559, 67–72. <https://doi.org/10.1038/s41586-018-0255-3>
- Zhuang, Y., Krumm, B., Zhang, H., Zhou, X.E., Wang, Y., Huang, X.-P., Liu, Y., Cheng, X., Jiang, Y., Jiang, H., Zhang, C., Yi, W., Roth, B.L., Zhang, Y., Xu, H.E., 2021. Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor. *Cell Res* 31, 593–596. <https://doi.org/10.1038/s41422-021-00482-0>